SPD422 (anagrelide hydrochloride)
SPD422-309
Phase 3 small_molecule completed
Quick answer
SPD422 (anagrelide hydrochloride) for Essential Thrombocythemia (ET) is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Essential Thrombocythemia (ET)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed